Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Eli Lilly and Co. and Purdue University announced today a significant expansion of their long-standing alliance ... innovation at every stage of the pharmaceutical pipeline.

INDIANAPOLIS and WEST LAFAYETTE, Ind. - Eli Lilly and Company (NYSE: LLY), a pharmaceutical giant with annual revenue exceeding $49 billion and an impressive 81.7% gross profit margin, and Purdue ...

Eli Lilly and Co. CEO David Ricks ... $250 million over the next eight years to foster pharmaceutical innovation. The initiative, called Lilly-Purdue 360, is focused on efforts including ...

In its second R&D alliance this week, Eli Lilly has formed a partnership with ... Earlier this week, the pharma group announced a $1 billion alliance with Swiss start-up Haya Therapeutics to ...

Sidekick is also working with a number of other pharma companies on companion ... and other chronic conditions. The new Lilly alliance is one of three that Sidekick expects to announce in the ...

Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera ... target collaboration and license agreement with Eli Lilly and Company (“Lilly”) targeting diabetes ...

The U.S. imports more pharmaceutical products from Ireland than from any other country -- nearly $50 billion last year. It won't be surprising if the Trump administration especially targets those ...

INDIANAPOLIS and WEST LAFAYETTE, May 9, 2025 — Eli Lilly and Company (NYSE: LLY) and Purdue University announced Friday (May 9) a significant expansion of their long-standing alliance ... at every ...

May 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance ... stage of the pharmaceutical pipeline.